ReviewCellular and molecular gastroenterology and hepatology2018
Engineered Livers for Infectious Diseases.
Review in Cellular and molecular gastroenterology and hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Applications and limitations of pluripotent stem cell-derived liver organoids.Chinese medical journal · 2026Review
- Organoids as preclinical models of human disease: progress and applications.Medical review (2021) · 2024Review
- Development of Plasmodium falciparum liver-stages in hepatocytes derived from human fetal liver organoid cultures.Nature communications · 2023Article
- Cell Culture Systems for Studying Hepatitis B and Hepatitis D Virus Infections.Life (Basel, Switzerland) · 2023Review
- Review
- Transcending Dimensions in Apicomplexan Research: from Two-Dimensional to Three-DimensionalMicrobiology and molecular biology reviews : MMBR · 2022Review
- Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids.Science advances · 2022Article
- Advancing Key Gaps in the Knowledge ofFrontiers in cellular and infection microbiology · 2022Review
- Review
- [A review on cell-based models of human liver disease in vitro].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2021Review
- Challenges for the Applications of Human Pluripotent Stem Cell-Derived Liver Organoids.Frontiers in cell and developmental biology · 2021Review
- Humanized Mice and the Rebirth of Malaria Genetic Crosses.Trends in parasitology · 2020Review
- In Vitro Systems for Studying Different Genotypes/Sub-Genotypes of Hepatitis B Virus: Strengths and Limitations.Viruses · 2020Review
- Liver Bioreactor Design Issues of Fluid Flow and Zonation, Fibrosis, and Mechanics: A Computational Perspective.Journal of functional biomaterials · 2020Review
- Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens.Frontiers in immunology · 2020Review
- Targeting liver stage malaria with metformin.JCI insight · 2019Article
- Review
- Emerging trends in modeling human liver diseaseAPL bioengineering · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered liver systems come in a variety of platform models, from 2-dimensional cocultures of primary human hepatocytes and stem cell-derived progeny, to 3-dimensional organoids and humanized mice. Because of the species-specificity of many human hepatropic pathogens, these engineered systems have been essential tools for biologic discovery and therapeutic agent development in the context of liver-dependent infectious diseases. Although improvement of existing models is always beneficial, and the addition of a robust immune component is a particular need, at present, considerable progress has been made using this combination of research platforms. We highlight advances in the study of hepatitis B and C viruses and malaria-causing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.